Skip to content
MARKETS / NYSE / RFL
NYSE · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Rafael Holdings, Inc. RFL

10 fiscal years on record · USD · FY2025 reported · SEC filings only
$30,000
▼ 95.3% YoY
$-30.5M
$-18.9M
Growth
USD 30,000.00
Revenue, FY2025 · full 10-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -30.5
-50M-100M2016201720182019202020212022202320242025
Compound annual growth
−58.2%
−63.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −63.9% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−102143 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -97196.7% · Net -102143.3%
-50000%-100000%2016201720182019202020212022202320242025
ROE
FY2025 · ROE -34.6%
-50%-100%2016201720182019202020212022202320242025

Each USD of equity lost 35 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -18.9
-10M-20M2016201720182019202020212022202320242025

Total assetsUSD 114.1M
EquityUSD 94.4M
CashUSD 52.8M
Current ratio4.89×

Equity funds 83% of total assets.

The 10-year record
10 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016
Revenue $B0.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.1−0.0−0.1−0.0−0.0−0.0−0.00.00.0
EBITDA $B··−0.0−0.1−0.0−0.0−0.0−0.00.00.0
Income tax $B−0.0−0.0−0.0·0.00.0−0.00.00.00.0
Net income $B−0.0−0.0−0.0−0.1−0.0−0.0−0.0−0.00.00.0
Free cash flow $B−0.0−0.0·−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−1.04−1.45−0.08−6.31−1.49−0.66−0.35−0.930.010.06
Dividend / sh $··········
Payout %··········
ROE %−34.6−37.7−1.9−111.9−19.3−9.4−4.3−14.60.3·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures · 1 divergences in 38 reconciliationsAUDITED

Reconciled in 9 of 19 fiscal years. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 54 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures1 divergent
ActivityPharmaceutical Preparations
Listed onNYSE
Incorporated inDelaware
Fiscal year endsJuly 31
SEC categorysmaller reporting company
Data on record since2016

Share this section

Download image